BlackRock Inc. Purchases Shares of 2,659,218 TriSalus Life Sciences, Inc. $TLSI

Key Points

• BlackRock acquired 2.66 million TriSalus Life Sciences shares worth approximately $12.1 million, giving it a 4.33% stake. Other institutional investors also adjusted their positions, though institutions collectively own only 2.58% of TLSI.
• TriSalus reported quarterly revenue of $11.41 million, above the $10.27 million consensus estimate, while its adjusted loss of $0.16 per share matched expectations.
• TLSI shares opened at $5.00, within a 52-week range of $2.20 to $7.95. Analysts maintain a consensus “Hold” rating with a $7.50 price target.

BlackRock Inc. bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,659,218 shares of the company's stock, valued at approximately $12,099,000. BlackRock Inc. owned approximately 4.33% of TriSalus Life Sciences at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in TLSI. Cura Wealth Advisors LLC acquired a new stake in TriSalus Life Sciences in the 2nd quarter valued at $36,000. JPMorgan Chase & Co. raised its stake in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after purchasing an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth approximately $47,000. Invesco Ltd. bought a new position in shares of TriSalus Life Sciences in the fourth quarter valued at approximately $72,000. Finally, Abel Hall LLC purchased a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $73,000. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Trading Up 0.4%

TriSalus Life Sciences stock opened at $5.00 on Friday. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. TriSalus Life Sciences, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The stock has a market cap of $307.90 million, a P/E ratio of -3.85 and a beta of 0.44. The firm's fifty day moving average price is $4.74 and its 200-day moving average price is $4.33.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TLSI. Weiss Ratings reissued a "sell (e+)" rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Lake Street Capital reduced their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 13th. Finally, Wall Street Zen raised shares of TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 23rd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

Want to see what other hedge funds are holding TLSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source